J&J

The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.

While the use of sequencing in disease research for both Mendelian and complex diseases continued to advance during the year, 2010 also saw the launch of several sequencing-based diagnostic tests, as well as pharmaceutical companies entering the sequencing field and the first examples of sequencing being used to make decisions on patient treatment.

The partners will develop a bench-top platform to isolate and explore the biology of rare cells at the protein, RNA, and DNA levels.

Johnson & Johnson Development Corporation was among the investors in the company's $22 million Series C financing round.

The company will use its lead discovery service to study compounds for J&JPRD.

Instead of focusing on whole-genome sequencing, which they all said was still too expensive, the three pharma companies are focusing on either specific genes, a portion of the exome, or the transcriptome.

SpeeDx, a spinout of Johnson & Johnson's Australian research subsidiary, claims its multi-component nucleic acid enzymes, or MNAzymes, provide significant advantages over current enzymes for multiplex qPCR applications.

The World Wide Web Consortium's Health Care and Life Sciences Interest Group is plotting a semantic course to help find ways for pharma to communicate across drug discovery and development phases.

Pairings

Premium

Eric Nelson; Call for Nominations for Dr. Paul Janssen Award

The Dutch array vendor is working closely with partners in the pharmaceutical industry and academia to optimize internally developed kinase-screening assays for use in drug discovery and as companion diagnostics.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.